We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
GymBuddy is an online platform that enables consumers to find, book, and attend a gym location, services, or products offered and operated by fitness studios, gyms, trainers, venues, or other third parties. Users can easily, through filtered searches on the app, view descriptions, and contact information of specialists within the fitness industry such as personal trainers, nutritionists, and physiotherapists. The UK fitness industry alone is currently worth over £5 billion. Based on recent statistics, the average gym membership in the UK costs members £40 a month, which often ties them into lengthy contracts. The GymBuddy app will enter the Health & Fitness club sector as a multi-gym membership feature that gives users access to gyms and various fitness plans, without the need for bricks-and-mortar locations under its brand. The company is seeking an investment of £400,000 to expand its brand identity and bring more users to its ecosystem to generate profits.

Pitch Rated

30%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
Sudor is a purpose-built platform for fitness professionals and their clients. The company claims to provide the technology and tools to empower fitness professionals as they build their digital business. Its core vision is to disrupt YouTube's fitness section that isn't purpose-built for fitness, doesn’t support challenges, track progress, or allows for 1:1 classes etc. Sudor asserts that its platform is different. It allows trainers to earn from their first subscriber. Trainers can also upload on-demand videos, stream live classes or create challenges for their subscribers. Sudor stresses that this gives its business ultimate scalability. It aspires to dominate the digital fitness industry in the US that is set to be worth $15 billion by 2026. The company has raised £465,000 to date, won the NOAH London Startup of the Year, and signed over 200 trainers. The portal hosts over 20,000 users and has paid out over £160,000 to trainers. The company states it will use the investment to scale Sudor worldwide.
days to go: Expired investment: £274,488
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £103,672
OnCare is a digital care management software that is digitising elderly care, creating a global care marketplace via the OpenTable model to care. OnCare provides care agencies with the power to plan, manage and enhance care delivery and staff communication. Their mission is to make care easier for everyone. OnCare is currently live with over 110 home-care agencies around the UK, and more than 1100 care workers. The company is planning to enter markets of Hong Kong, Canada and Israel. With the proceeds, the company will use this fund for people, office space, technology, software, hosting and marketing.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £96,040
Buildy is an online platform that aims at making construction hiring easy by eliminating the expensive middlemen, thereby, saving time and money for both employers and employees. The platform was shortlisted as the Best Recruitment Innovation at Building Innovation Awards. Buildy has already signed up around 100 tradespeople and 46 employers. The company will streamline the hiring process through automation of job by bidding for jobs, matching algorithms, ratings, online chat, reviews, and providing the skilled workers and tradespeople more control via a better user interface. With the proceeds, the company will seek to fast track the Buildy app and help the company become the top recognised brand in construction staff hiring.
days to go: Expired investment: £17,380
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £142,026
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph